Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Trial Profile

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 7442 (Primary) ; AZD 7442 (Primary) ; Bamlanivimab (Primary) ; BRII-196 (Primary) ; BRII-198 (Primary) ; C135-LS+C144-LS (Primary) ; Camostat mesilate (Primary) ; Interferon beta-1a (Primary) ; SAB-185 (Primary)
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACTIV-2; Adapt Out COVID
  • Most Recent Events

    • 29 Apr 2021 According to an Barii Bioscience media release, the Phase 3 portion of the study, which has been actively enrolling participants, is expanding into international trial sites, allowing for a broader assessment of the BRII-196 and BRII-198 combination in ambulatory COVID-19 patients, potentially including data against newly emerged SARS-CoV2 variants endemic to those countries.
    • 29 Apr 2021 According to an Barii Bioscience media release, the company today announced that its monoclonal antibody combination therapy, BRII-196 and BRII-198, met pre-specified safety and efficacy criteria, permitting continuation of this trial as recommended by a Independent data safety monitoring board (DSMB). This recommendation is based on an analysis reviewed by the DSMB of approximately 220 patients enrolled in the Phase 2 portion of the study.
    • 21 Apr 2021 According to an SAB Biotherapeutics media release, the company announced that the first patient has been dosed with SAB-185 in this Phase 2/3.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top